- Home
- PRG vs MNKD Comparison
PRG vs MNKD Comparison
Compare PRG & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRG
- MNKD
- Stock Information
- Founded
- PRG 2020
- MNKD 1991
- Country
- PRG United States
- MNKD United States
- Employees
- PRG N/A
- MNKD N/A
- Industry
- PRG Diversified Commercial Services
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- PRG Consumer Discretionary
- MNKD Health Care
- Exchange
- PRG Nasdaq
- MNKD Nasdaq
- Market Cap
- PRG 1.8B
- MNKD 1.8B
- IPO Year
- PRG N/A
- MNKD 2004
- Fundamental
- Price
- PRG $42.11
- MNKD $6.85
- Analyst Decision
- PRG Buy
- MNKD Strong Buy
- Analyst Count
- PRG 6
- MNKD 7
- Target Price
- PRG $53.00
- MNKD $8.71
- AVG Volume (30 Days)
- PRG 423.4K
- MNKD 3.3M
- Earning Date
- PRG 02-19-2025
- MNKD 11-07-2024
- Dividend Yield
- PRG 1.14%
- MNKD N/A
- EPS Growth
- PRG 8.67
- MNKD N/A
- EPS
- PRG 3.58
- MNKD 0.08
- Revenue
- PRG $2,417,577,000.00
- MNKD $267,200,000.00
- Revenue This Year
- PRG $2.85
- MNKD $45.36
- Revenue Next Year
- PRG $6.70
- MNKD $16.99
- P/E Ratio
- PRG $11.76
- MNKD $86.40
- Revenue Growth
- PRG N/A
- MNKD 51.35
- 52 Week Low
- PRG $27.84
- MNKD $3.17
- 52 Week High
- PRG $50.28
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- PRG 30.82
- MNKD 56.28
- Support Level
- PRG $46.02
- MNKD $5.81
- Resistance Level
- PRG $44.86
- MNKD $6.42
- Average True Range (ATR)
- PRG 1.53
- MNKD 0.32
- MACD
- PRG -0.67
- MNKD -0.01
- Stochastic Oscillator
- PRG 13.58
- MNKD 82.54
About PRG PROG Holdings Inc.
PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The Company has two reportable segments: (i) Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and (ii) Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the progressive leasing segment.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.